The U.S. Food and Drug Administration (FDA) on Wednesday approved a new pancreatic cancer drug that could usher in a new era for treating one of the most lethal forms of the disease. Developed by the American biotech startup Revolution Medicines, the treatment will be marketed under the brand name 'Rasonk.' Clinical trials revealed that the medication can double survival time for a specific subset of patients. In an official statement, FDA official Kyle Diamantas highlighted the breakthrough, noting that the drug provides 'a critical new option for patients facing a highly challenging type of cancer that has historically proven exceptionally difficult to treat.' While the oral tablet is not a cure, it has generated significant enthusiasm among oncologists and patient advocacy groups for offering those diagnosed with this aggressive malignancy a chance at extending their lives by several valuable months. Utilizing an active molecule known as daraxonrasib, the drug demonstrated efficacy far surpassing that of conventional chemotherapy during clinical trials.
The U.S. Food and Drug Administration (FDA) on Wednesday approved a new pancreatic cancer drug that could usher in a new era for treating one of the most lethal forms of the disease. Developed by the American biotech startup Revolution Medicines, the treatment will be marketed under the brand name 'Rasonk.' Clinical trials revealed that the medication can double survival time for a specific subset of patients. In an official statement, FDA official Kyle Diamantas highlighted the breakthrough, noting that the drug provides 'a critical new option for patients facing a highly challenging type of cancer that has historically proven exceptionally difficult to treat.' While the oral tablet is not a cure, it has generated significant enthusiasm among oncologists and patient advocacy groups for offering those diagnosed with this aggressive malignancy a chance at extending their lives by several valuable months. Utilizing an active molecule known as daraxonrasib, the drug demonstrated efficacy far surpassing that of conventional chemotherapy during clinical trials.
The U.S. Food and Drug Administration (FDA) on Wednesday approved a new pancreatic cancer drug that could usher in a new era for treating one of the most lethal forms of the disease. Developed by the American biotech startup Revolution Medicines, the treatment will be marketed under the brand name 'Rasonk.' Clinical trials revealed that the medication can double survival time for a specific subset of patients. In an official statement, FDA official Kyle Diamantas highlighted the breakthrough, noting that the drug provides 'a critical new option for patients facing a highly challenging type of cancer that has historically proven exceptionally difficult to treat.' While the oral tablet is not a cure, it has generated significant enthusiasm among oncologists and patient advocacy groups for offering those diagnosed with this aggressive malignancy a chance at extending their lives by several valuable months. Utilizing an active molecule known as daraxonrasib, the drug demonstrated efficacy far surpassing that of conventional chemotherapy during clinical trials.
comments
FDA Approves New Pancreatic Cancer Drug Offering Hope Against Lethal Form
display options :
Full
Main image only
without images
comments